Clinical Trials Directory

If you choose to join this study, you will:

• Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
• Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
• Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2

This study has three smaller parts called Sub Studies. In Sub Study 1, people receive a medicine called duvakitug. In Sub Study 2, people are placed by chance into one of three groups to receive duvakitug or a placebo. In Sub Study 3, people are placed by chance into one of two dose groups to receive duvakitug. The whole study lasts about 35 weeks and includes about 15 visits. During the visits, you will have heart tests, blood tests, an endoscopy with a biopsy, and questionnaires. When you join the study, you will be put into either Sub Study 1 or Sub Study 2. You will take the study medicine every two weeks for 12 weeks. After you finish Sub Study 1 or Sub Study 2, you may be asked to join Sub Study 3 to take duvakitug for another 12 weeks, or you may be asked to join another study called SUNSCAPE 2.

We are doing this study to find out if an investigational, non-stimulant drug called SPN-812 (the study drug, viloxazine extended-release capsules). The study drug is FDA-approved for children ages 6 and above. It is not approved for children younger than 6, so this study is being done to determine how well it works and how safe it is for preschool-aged children.

We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.

The SYNCHRONICITY study is a test to compare two treatments for people with heart failure and a heart electrical problem called left bundle branch block. People in the study will be randomly chosen to get one of two devices: a new type called LBBAP or a regular type called CRT. First, they will have surgery to put in the device. Then, they will have checkups at 6 months, 12 months, and once a year for up to 5 years. At these visits, doctors will check the device, do heart tests, and ask how the person feels. The study wants to find out which device is safer and works better.

We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.